NCT04599140View on ClinicalTrials.gov

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal AdenocarcinomaStage III Colon Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Colon Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Rectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Stage IVC Rectal Cancer AJCC v8Unresectable Colon AdenocarcinomaUnresectable Rectal Adenocarcinoma
Interventions
DRUG

CXCR1/2 Inhibitor SX-682

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Syntrix Biosystems, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER